CYP19A1 Aromatase

LE WE PMID CA

CYP19A1 Aromatase

218

CYP19A1 Aromatase

11 hydoxylase

17 20 Desmolase

17 alpha hydroxylase 17 20 lyase

17 beta hydroxysteroid dehydrogenase

20 22 Desmolase

21 hydroxylase deficiency

3 beta hydroxysteroid dehydrogenase2

5 alpha Reductase

Adrenal gland (Hyperplasia congenital)

Anastrozole

Androgen insensitivity syndrome

Congenital adrenal hyperplasia

CYP19A1 Aromatase

DAX1 NR0B1

Endometriosis

Growth retardation

GS alpha

Gynecomastia

HSD17B3

KAL

Kallmann s syndrome

Leptin

Letrozole

LH

Mammary gland (Neoplasia)

McCune Albright syndrome

Natural products

NR5A1 SF1

PC1

Pituitary gland (Insufficiency Panhypopituitarism)

PROP1

Puberty (BASKET)

Puberty (Delayed)

Puberty (Precocious)

Receptor (Androgen)

Receptor (Estrogen)

Receptor (FSH)

Receptor (Glucocorticoid)

Receptor (GnRH)

Receptor (LH)

StAR

2005 1	Regulation of aromatase expression in estrogen-responsive breast and uterine disease: from bench to treatment. [16109840] Pharmacol Rev 57(3): 359-83 (2005)
2002 2	Aromatase and its inhibitors: significance for breast cancer therapy. [12017550] Recent Prog Horm Res 57(-): 317-38 (2002)
2008 3	Practical guidance for the management of aromatase inhibitor-associated bone loss. [18448451] Ann Oncol 19(8): 1407-16 (2008)
2005 4	Aromatase inhibition: translation into a successful therapeutic approach. [15837728] Clin Cancer Res 11(8): 2809-21 (2005)
2003 5	Clinical differences among the aromatase inhibitors. [12538503] Clin Cancer Res 9(1 Pt 2): 473S-9S (2003)
2003 6	Pharmacology and pharmacokinetics of the newer generation aromatase inhibitors. [12538502] Clin Cancer Res 9(1 Pt 2): 468S-72S (2003)
2001 7	Advances in aromatase inhibition: clinical efficacy and tolerability in the treatment of breast cancer. [11555572] Clin Cancer Res 7(9): 2620-35 (2001)
2008 8	Aromatase inhibitors: are there differences between steroidal and nonsteroidal aromatase inhibitors and do they matter? [18695261] Oncologist 13(8): 829-37 (2008)
2006 9	Appraising adjuvant aromatase inhibitor therapy. [17110624] Oncologist 11(10): 1058-69 (2006)
2001 10	Minireview: aromatase and the regulation of estrogen biosynthesis--some new perspectives. [11606422] Endocrinology 142(11): 4589-94 (2001)
2008 11	Use of aromatase inhibitors in children and adolescents with disorders of growth and adolescent development. [18381525] Pediatrics 121(4): e975-83 (2008)
2002 12	Clinical review 148: Monogenic disorders of puberty. [12050203] J Clin Endocrinol Metab 87(6): 2481-94 (2002)
2009 13	History of aromatase: saga of an important biological mediator and therapeutic target. [19389994] Endocr Rev 30(4): 343-75 (2009)
2011 14	A critical evaluation of the role of aromatase inhibitors as adjuvant therapy for postmenopausal women with breast cancer. [21502311] Endocr Relat Cancer 18(3): R79-89 (2011)
2011 15	The emerging use of aromatase inhibitors for endometriosis treatment. [21693036] Reprod Biol Endocrinol 9(-): 87 (2011)
2011 16	Use of aromatase inhibitors to treat endometriosis-related pain symptoms: a systematic review. [21693038] Reprod Biol Endocrinol 9(-): 89 (2011)
2011 17	Potential utility of natural products as regulators of breast cancer-associated aromatase promoters. [21693041] Reprod Biol Endocrinol 9(-): 91 (2011)
2008 18	Aromatase expression in the ovary: hormonal and molecular regulation. [18321551] Steroids 73(5): 473-87 (2008)

Downloaded from http://www.kidney.de - The Database of Free Medical Reviews - The Metatextbook of Medicine - Ossip Groth

All Medline data shown were primarily retrieved from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Fatal error: Uncaught Error: Call to undefined function mysql_connect() in C:\Inetpub\vhosts\kidney.de\httpdocs\bdom\CYP19A1 Aromatase.php:92 Stack trace: #0 {main} thrown in C:\Inetpub\vhosts\kidney.de\httpdocs\bdom\CYP19A1 Aromatase.php on line 92